Abs 268: @HiraSMian presents data on >5700 pts with MM from Canadian registry with some good/some sobering news for #geriheme pts:
1. ASCT use rising
2. 60% of older pts get a novel drug
3. 20% 1-yr mortality
4. 30% of older patients received NO MYELOMA TREATMENT
#ASH19
1. ASCT use rising
2. 60% of older pts get a novel drug
3. 20% 1-yr mortality
4. 30% of older patients received NO MYELOMA TREATMENT
#ASH19
Even with universal coverage, older pts, lower SES or more comorbidities less likely to be treated for myeloma #mmsm #geriheme #ASH19 
High 1-yr mortality for older pts with myeloma who don’t receive treatment. We saw similar rate untreated in SEER- Medicare database. #geriheme ncbi.nlm.nih.gov/m/pubmed/29429…
Will be curious to hear hypotheses about why the plateau? Payor or provider factors?
13% of pts over age 65 get ASCT... have to check but I think it is single digit % in US in >65.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
